Pharma
Jubilant Pharmova Ltd
JUBLPHARMA · NSE · INE700A01033Wednesday, 9 Sept 20262:32 pm
Market Cap—
P/E—
P/B—
EPS—
Div Yield—
ROE6.0%
ROCE4.7%
ROE6.0%
1Y Return-3.04%
Avg. Volume0.3M
Price Chart
52-Week Range
About
Jubilant Pharmova Ltd is a Pharma company listed on NSE.
Technicals
Free account
Register freeTechnicals
Create a free account to view momentum, moving averages, and delivery signals.
Quant
Premium
UpgradeQuant metrics
Upgrade to view volatility, drawdown, factor, and risk metrics.
Key Ratios
Market Cap—
Current Price₹1,018.3
52W High / Low₹1,184.8 / ₹786.05
Stock P/E—
Price to Book—
EPS (TTM)—
Dividend Yield—
ROE6.0%
1Y Return-3.04%
Day Change+2.06%
Profit & Loss
| Period | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Sales | ₹8,225 Cr | ₹7,192 Cr | ₹6,645 Cr | |
| Expenses | ₹7,406 Cr | ₹6,385 Cr | ₹6,122 Cr | |
| Operating Profit | ₹819 Cr | ₹807 Cr | ₹523 Cr | |
| OPM % | 10.0% | 11.2% | 7.9% | |
| Other Income | ₹16 Cr | ₹20 Cr | ₹15 Cr | |
| Depreciation | ₹440 Cr | ₹369 Cr | ₹382 Cr | |
| Interest | ₹201 Cr | ₹221 Cr | ₹256 Cr | |
| Profit Before Tax | ₹614 Cr | ₹981 Cr | ₹171 Cr | |
| Tax | ₹217 Cr | ₹144 Cr | ₹98 Cr | |
| Net Profit | ₹398 Cr | ₹836 Cr | ₹73 Cr | |
| EPS (₹) | 25.1 | 52.9 | 4.9 | |
| Dividend Payout % | — | — | — |
Financial history locked
Register freeRegister free to see 1 more year.
Quarterly Results
| Quarter | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| Sales | ₹2,221 Cr | ₹2,272 Cr | ₹2,116 Cr | ₹1,879 Cr | |
| Expenses | ₹2,100 Cr | ₹2,050 Cr | ₹1,947 Cr | ₹1,687 Cr | |
| Operating Profit | ₹121 Cr | ₹223 Cr | ₹169 Cr | ₹192 Cr | |
| OPM % | 5.4% | 9.8% | 8.0% | 10.2% | |
| Depreciation | — | — | — | — | |
| Interest | ₹54 Cr | ₹57 Cr | ₹56 Cr | ₹49 Cr | |
| Net Profit | ₹56 Cr | ₹119 Cr | ₹56 Cr | ₹103 Cr | |
| EPS (₹) | 3.6 | 7.5 | 3.5 | 6.5 |
Quarterly history locked
Register freeRegister free to see 1 more quarter.
Balance Sheet
| Period | FY26 | FY25 | FY24 | FY23 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹16 Cr | ₹16 Cr | ₹16 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹7,077 Cr | ₹6,239 Cr | ₹5,418 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹3,615 Cr | ₹2,731 Cr | ₹3,664 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹4,815 Cr | ₹3,771 Cr | ₹2,451 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹15,523 Cr | ₹12,756 Cr | ₹11,549 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹6,922 Cr | ₹5,179 Cr | ₹3,841 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹1 Cr | ₹8 Cr | ₹8 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | ₹1,070 Cr | ₹892 Cr | ₹916 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | ₹1,232 Cr | ₹1,129 Cr | ₹1,290 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | ₹1,265 Cr | ₹1,086 Cr | ₹954 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹5,034 Cr | ₹4,463 Cr | ₹4,540 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹15,523 Cr | ₹12,756 Cr | ₹11,549 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance sheet history locked
Register freeRegister free to see 1 more year.
Cash Flow
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| FY26 | ₹1,227 Cr | ₹-1,260 Cr | ₹95 Cr | ₹62 Cr |
| FY25 | ₹1,072 Cr | ₹488 Cr | ₹-1,453 Cr | ₹107 Cr |
| FY24 | ₹971 Cr | ₹-608 Cr | ₹-433 Cr | ₹-69 Cr |
| FY23 |
Cash flow history locked
Register freeRegister free to see 1 more year.
Peer Comparison
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | — | — | +14.78% | +7.18% |
| Dr Reddys Laboratories Ltd | — | — | +8.84% | -3.74% |
| Cipla Ltd | — | — | +11.77% | -5.50% |
| Apollo Hospitals Enterprise Ltd | — | — | +22.64% | +23.01% |
| Divis Laboratories Ltd | ₹2,50,065 Cr | 83.9 | +16.5% | +46.29% |
Mutual Fund Holdings
Free account
Register freeMutual fund holdings
Create a free account to see institutional ownership snapshots.
Bulk & Block Deals
Free account
Register freeBulk & block deals
Create a free account to view recent institutional deal activity.
Analyst Estimates
Free account
Register freeAnalyst estimates
Create a free account to view analyst estimate summaries.
Documents & Filings
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.